Yeah I saw that, insiders have been selling all year from what Etrade is showing. I picked up some puts here last Friday, looks like that run ran out of steam. imo
7:13AM Regeneron Pharms beats by $0.23, misses on revs; raises FY12 EYLEA sales forecast (REGN) 102.08 : Reports Q4 (Dec) loss of $0.37 per share, $0.23 better than the Capital IQ Consensus Estimate of ($0.60); revenues fell 8.0% year/year to $123 mln vs the $129.18 mln consensus. Co sees Full Year 2012 EYLEA US sales increased to $250-300 mln from $140-160 mln prior guidance